The result showed that PD-1 mAb increased the death rates of T cells (CD45+CD3+ Annexin V+) and NK cells (CD45+CD3−CD19− Annexin V+) of several NSCLC patients (patient No. 1, and No. 6-8) in a dose-dependent way (Fig. 1C and Fig. S2). Here, PDCD1 is linked to non-small cell lung carcinoma.